NAD on One-A-Day
This article was originally published in The Tan Sheet
Executive Summary
Bayer HealthCare should discontinue advertising claims stating that men can reduce their risk of prostate cancer by taking One-A-Day Men's Health Formula, the watchdog group concludes in a recent Case Report. Although Bayer cited Harvard Medical School studies linking lycopene to prostate health, ad claims conveyed a message that was "much broader than the evidence could support," NAD maintains. The ad depicts a fire chief who advises his coworkers to switch to One-A-Day Men's when he learns that "one in three men face prostate cancer." Bayer provided reasonable scientific evidence to support the link between lycopene and prostate health, NAD says, but the ad's "tone of concern" and backdrop "make it reasonable for consumers to take away a message that taking One-A-Day has a cancer preventive effect because it contains lycopene"...
You may also be interested in...
NAD Weight-Loss Claims Bulk Up In 2004; Whitening Cases Lose Luster
Nearly half of the National Advertising Division cases involving the OTC drug, dietary supplement and oral care markets thus far in 2004 were initiated by the watchdog group, and not brought forward by a competing company
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.